DexCom‘s patent involves a glucose monitoring system with a sensor that calculates in vivo sensitivity without needing a reference analyte measurement post-insertion. The system uses in vitro sensitivity pre-insertion to estimate glucose levels, improving accuracy and efficiency in monitoring blood sugar levels for users. GlobalData’s report on DexCom gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights DexCom Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on DexCom, Medical data analysis was a key innovation area identified from patents. DexCom's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Glucose monitoring system with in vivo and ex vivo portions

Source: United States Patent and Trademark Office (USPTO). Credit: DexCom Inc

A recently granted patent (Publication Number: US11883164B2) discloses a glucose monitoring system that includes a transcutaneous electrochemical glucose sensor with both in vivo and ex vivo portions. The system is equipped with at least one processor programmed to calculate the in vivo sensitivity of the sensor by converting the in vitro sensitivity obtained prior to insertion. This calculated sensitivity is then used to determine an estimated glucose value based on in vivo measurements, eliminating the need for reference analyte measurements post-insertion. The system also features a temperature probe for temperature compensation and a housing for mounting on the skin of the host, with processors positioned within the housing and a receiver with a display.

Furthermore, the patent describes a method for making the glucose monitoring system, involving applying a predictive relationship to convert the in vitro sensitivity to glucose to an in vivo sensitivity. This method allows for the calibration of data derived from in vivo measurements without requiring post-insertion reference glucose measurements. The in vivo sensitivity is derived from the predictive relationship, which is based on in vitro testing of the sensor. The method also highlights the greater in vivo sensitivity compared to the in vitro sensitivity and the utilization of benchtop testing for sensitivity derivation. This innovative system aims to provide accurate glucose monitoring without the need for invasive reference measurements, enhancing user experience and convenience in glucose management.

To know more about GlobalData’s detailed insights on DexCom, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.